Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Viral clearance 15% Improvement Relative Risk HCQ for COVID-19  Brouqui et al.  EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Retrospective 1,276 patients in France (March 2020 - March 2021) Improved viral clearance with HCQ (p=0.037) c19hcq.org Brouqui et al., Authorea, Inc., March 2023 Favors HCQ Favors control

Viral clearance in patients with COVID-19: associated factors and the role of antiviral treatment

Brouqui et al., Authorea, Inc., doi:10.22541/au.167948825.59270994/v1
Mar 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Retrospective 1,276 patients in France, showing faster viral clearance with HCQ treatment.
risk of no viral clearance, 15.3% lower, HR 0.85, p = 0.04, treatment 776, control 500, adjusted per study, inverted to make HR<1 favor treatment, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Brouqui et al., 22 Mar 2023, retrospective, France, preprint, 8 authors, study period 3 March, 2020 - 13 March, 2021.
This PaperHCQAll
Viral clearance in patients with COVID-19: associated factors and the role of antiviral treatment
Philippe Brouqui, Jean-Christophe Lagier, P Parola, M Million, S Cortaredona, Léa Delorme, Philippe Colson, Didier Raoult
doi:10.22541/au.167948825.59270994/v1
The role of hydroxychloroquine (HCQ) in lowering the viral load of patients with COVID-19 is controversial. In our Institute, we treated more than 30,000 people with COVID-19 in 2020 and 2021, using the same diagnostic tools and the same treatment dosages. In this retrospective comparative study of data collected over this period, we aimed to compare the viral clearance in the nasopharynx as determined by qPCR in patients who were treated with HCQ and those who were not. As a new feature, we adjusted the data according to the most significant confounding factors (age, initial viral load, and timescale between the onset of symptoms and treatment). Of the 1 276 patients selected from our database, 776 were treated with HCQ and 500 were not. Viral clearance in the treatment group was reached significantly earlier than in the non-treatment group, at days 5, 10 and 30. These differences remain significant after adjustments for confounding factors. In conclusion, although age, initial viral load, and time to treatment do influence the viral load in patients with COVID-19, hydroxychloroquine associated with azithromycin still independently significantly lowered viral load more rapidly than other treatments, including azithromycin alone.
Hosted file Table 1 .docx available at https://authorea.com/users/410460/articles/631056-viral-clearancein-patients-with-covid-19-associated-factors-and-the-role-of-antiviral-treatment Hosted file Table 2 .docx available at https://authorea.com/users/410460/articles/631056-viral-clearancein-patients-with-covid-19-associated-factors-and-the-role-of-antiviral-treatment Hosted file Table 3 .docx available at https://authorea.com/users/410460/articles/631056-viral-clearancein-patients-with-covid-19-associated-factors-and-the-role-of-antiviral-treatment
References
Ader, Peiffer-Smadja, Poissy, Bouscambert-Duchamp, Belhadi et al., An openlabel randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19, Clin Microbiol Infect
Ahmad, Eze, Noulin, Horvathova, Murray et al., EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge, N Engl J Med
Asberg, Humar, Rollag, Jardine, Mouas et al., Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients, Am J Transplant
Biber, Harmelin, Ram, Shaham, Nemet, The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 -a double-blind, randomized placebo-controlled trial, Int J Infect Dis
Chanouzas, Dyall, Nightingale, Ferro, Moss et al., Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CAN-VAS): study protocol for a randomised controlled trial, Trials
Fine, Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk, Journal of the American Statistical Association
Gautret, Hoang, Lagier, Raoult, Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes, International Journal of Antimicrobial Agents
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Hirai, Nishioka, Sekine, Nishihara, Okuda et al., Factors associated with viral clearance periods from patients with COVID-19: A retrospective observational cohort study, J Infect Chemother
Jaafar, Aherfi, Wurtz, Grimaldier, Hoang et al., Correlation between 3790 qPCR positives samples and positive cell cultures including 1941 SARS-CoV-2 isolates, Clin Infect Dis
Lagier, Million, Gautret, Colson, Cortaredona et al., None, Outcomes
Long, Zhao, Zeng, Lu, Fang et al., Prolonged viral shedding of SARS-CoV-2 and related factors in symptomatic COVID-19 patients: a prospective study, BMC Infect Dis
Owusu, Pomeroy, Lewis, Wadhwa, Yousaf et al., Persistent SARS-CoV-2 RNA Shedding Without Evidence of Infectiousness: A Cohort Study of Individuals With COVID-19, J Infect Dis
Puhach, Meyer, Eckerle, SARS-CoV-2 viral load and shedding kinetics, Nat Rev Microbiol
Recovery Collaborative Group, Horby, Mafham, Linsell, Bell et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med
Rojas, Rodríguez, Hernández, Díaz-Coronado, Vergara et al., Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study, BMC Infect Dis
Schooley, Correlation between viral load measurements and outcome in clinical trials of antiviral drugs, AIDS
Van Wyk, Ajana, Bisshop, Wit, Osiyemi et al., Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study, Clin Infect Dis
Ventura-López, Cervantes-Luevano, Aguirre-Sánchez, Flores-Caballero, Alvarez-Delgado et al., Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial, Biomed Pharmacother
Xu, Chen, Yuan, Yi, Ding et al., Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19), Clin Infect Dis
Zhang, Chen, Chen, Guo, Zhou et al., The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases, Medicine
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit